834 reports of this reaction
1.5% of all BUMETANIDE reports
#18 most reported adverse reaction
OEDEMA PERIPHERAL is the #18 most commonly reported adverse reaction for BUMETANIDE, manufactured by Validus Pharmaceuticals LLC. There are 834 FDA adverse event reports linking BUMETANIDE to OEDEMA PERIPHERAL. This represents approximately 1.5% of all 57,117 adverse event reports for this drug.
Patients taking BUMETANIDE who experience oedema peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OEDEMA PERIPHERAL is a less commonly reported adverse event for BUMETANIDE, but still significant enough to appear in the safety profile.
In addition to oedema peripheral, the following adverse reactions have been reported for BUMETANIDE:
The following drugs have also been linked to oedema peripheral in FDA adverse event reports:
OEDEMA PERIPHERAL has been reported as an adverse event in 834 FDA reports for BUMETANIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OEDEMA PERIPHERAL accounts for approximately 1.5% of all adverse event reports for BUMETANIDE, making it a notable side effect.
If you experience oedema peripheral while taking BUMETANIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.